Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P47869

UPID:
GBRA2_HUMAN

ALTERNATIVE NAMES:
GABA(A) receptor subunit alpha-2

ALTERNATIVE UPACC:
P47869; A8K0U7; B7Z1H8; Q59G14

BACKGROUND:
The Gamma-aminobutyric acid receptor subunit alpha-2 is integral for synaptic inhibition in the brain, acting as a component of the GABA(A) receptor. It is vital for the rapid formation of active synaptic contacts, with its function influenced by the presence of specific alpha and beta subunits in the receptor pentamer.

THERAPEUTIC SIGNIFICANCE:
Linked to Developmental and Epileptic Encephalopathy 78, a condition marked by refractory seizures and profound intellectual disability, Gamma-aminobutyric acid receptor subunit alpha-2's study offers a promising avenue for developing targeted therapies for epilepsy and cognitive disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.